News Feed Item

FDA Approvals, Definitve Agreements, Prestigious Recognitions, and Stock Summaries - Analyst Notes on Mallinckrodt, Novo Nordisk, Charles River Laboratories, Cerner, and Quintiles

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, March 18, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Novo Nordisk A/S (NYSE: NVO), Charles River Laboratories International, Inc. (NYSE: CRL), Cerner Corporation (NASDAQ: CERN), and Quintiles Transnational Holdings Inc. (NYSE: Q). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Mallinckrodt  plc  Analyst  Notes

On March 12, 2014, Mallinckrodt plc (Mallinckrodt) announced the U.S. Food and Drug Administration's (FDA) approval of XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), formerly known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options are ineffective. According to Mallinckrodt, the approval is partly based on the pivotal Phase 3 efficacy study conducted in an acute post-surgical pain model. The Company stated that XARTEMIS XR met the study's primary endpoint and showed statistically significant improvement in pain scores compared to placebo from baseline over 48 hours. Commenting on the approval, Mark Trudeau, President and CEO of Mallinckrodt, stated, "The FDA approval of XARTEMIS XR exemplifies Mallinckrodt's dedication to developing and providing new treatment options for people with pain. Mallinckrodt remains committed to continuing its work to develop innovative formulations for our product lines to help ensure access to appropriate pain treatment for the millions of patients suffering from acute pain, and we will continue to work closely with the FDA as we engage in further development programs for XARTEMIS XR and other products utilizing this technology platform." The full analyst notes on Mallinckrodt plc are available to download free of charge at:


Novo  Nordisk  A/S  Analyst  Notes

On March 12, 2014, Novo Nordisk A/S' (Novo Nordisk) stock declined 1.03%, closing at $46.02. For the past three-day trading period, the Company's stock went down by 2.91%, compared to the Dow Jones Industrial Average which lost 0.68% during the same three-day trading period. The full analyst notes on Novo Nordisk A/S are available to download free of charge at:


Charles  River  Laboratories  International,  Inc.  Analyst  Notes

On March 13, 2014, Charles River Laboratories International, Inc. (Charles River Laboratories) announced that it has entered into a definitive agreement to acquire the contract research organization (CRO) services division of Galapagos NV, including both Argenta and BioFocus for a purchase price of €129 million in cash or c. $179 million. According to Charles River Laboratories, the acquisition will position the Company as a full service, early-stage CRO, with integrated in vitro and in vivo capabilities from target discovery through preclinical development. Additionally, the Company stated that along with the initial purchase price, the transaction also includes future performance payments of up to €5 million or c. $7 million. Commenting on the release, James C. Foster, Chairman, President and CEO of Charles River Laboratories stated, "We believe that this acquisition expands our unique drug discovery and early-stage development focus and advances Charles River's position as a market leader in the fast-growing outsourced discovery services market." He concluded, "The acquisition will enhance our sales growth rate and be accretive to non-GAAP earnings per share in 2014, and we expect increased contribution in 2015 and beyond." The full analyst notes on Charles River Laboratories International, Inc. are available to download free of charge at:


Cerner  Corporation  Analyst  Notes

On March 12, 2014, Cerner Corporation's (Cerner) stock declined 0.13%, to close at $59.86. Over the past one-month trading period, Cerner shares increased by 3.29%, compared to the Nasdaq Composite which went up by 2.89% during the same trading session. The full analyst notes on Cerner Corporation are available to download free of charge at:


Quintiles  Transnational  Holdings  Inc.  Analyst  Notes

On March 12, 2014, Quintiles Transnational Holdings Inc. (Quintiles) reported that for the third time, the Company has been named as the "Best CRO in Asia" at the 2014 BioPharma Asia Industry Awards dinner. According to the Company, the award recognizes the contract research organization that has best demonstrated an ongoing commitment to improve clinical research in Asia and help customers succeed. Ken Lee, M.D., Quintiles Vice President and Regional General Manager for Southeast Asia, who accepted the award, stated, "This award reflects Quintiles' ability to improve our customers' probability of success by combining market knowledge with superior service. For 20 years we've been helping our customers navigate Asia's complex and changing healthcare environment. It's wonderful to be acknowledged for our excellence in bringing knowledge and people together for a healthier world." The full analyst notes on Quintiles Transnational Holdings Inc. are available to download free of charge at:


About  Analysts  Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.



  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For  any  urgent  concerns  or  inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
As IoT continues to increase momentum, so does the associated risk. Secure Device Lifecycle Management (DLM) is ranked as one of the most important technology areas of IoT. Driving this trend is the realization that secure support for IoT devices provides companies the ability to deliver high-quality, reliable, secure offerings faster, create new revenue streams, and reduce support costs, all while building a competitive advantage in their markets. In this session, we will use customer use cases...
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
The IoT Will Grow: In what might be the most obvious prediction of the decade, the IoT will continue to expand next year, with more and more devices coming online every single day. What isn’t so obvious about this prediction: where that growth will occur. The retail, healthcare, and industrial/supply chain industries will likely see the greatest growth. Forrester Research has predicted the IoT will become “the backbone” of customer value as it continues to grow. It is no surprise that retail is ...
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of bus...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
DXWorldEXPO LLC announced today that "Miami Blockchain Event by FinTechEXPO" has announced that its Call for Papers is now open. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Financial enterprises in New York City, London, Singapore, and other world financial capitals are embracing a new generation of smart, automated FinTech that eliminates many cumbersome, slow, and expe...
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER give you detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPO also offers s...
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
@DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises - and delivering real results.